RGLS (Regulus Therapeutics) Future 3-5Y EPS without NRI Growth Rate : -13.31 (As of May. 09, 2025)

View and export this data going back to 2012. Start your Free Trial

What is Regulus Therapeutics Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Regulus Therapeutics's Future 3-5Y EPS without NRI Growth Rate is -13.31.

Competitive Comparison of Regulus Therapeutics's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Regulus Therapeutics's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regulus Therapeutics's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regulus Therapeutics's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Regulus Therapeutics's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Regulus Therapeutics (NAS:RGLS) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Regulus Therapeutics Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Regulus Therapeutics's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Regulus Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regulus Therapeutics Inc (NAS:RGLS) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

7RG0:Germany 7RG0:Germany

Address

4224 Campus Point Court, Suite 210, San Diego, CA, USA, 92121

Website

https://www.regulusrx.com

Regulus Therapeutics Inc is a biotechnology company focused on the development of microRNA therapies. MicroRNA therapies target diseases such as cancer, metabolic diseases, fibrosis, and inflammatory diseases. The product candidate of the company is RGLS8429, an anti-miR next-generation oligonucleotide targeting miR-17 for the treatment of autosomal dominant polycystic kidney disease (ADPKD), and is in Phase 1b clinical development.

Executives

David Baltimore	director	AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Joseph P Hagan	officer: Chief Operating Officer	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Christopher Ray Aker	officer: Sr. VP & General Counsel	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Crispina Calsada	officer: Chief Financial Officer	C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Preston Klassen	officer: President & Head of R & D	3344 N. TORREY PINES COURT, SUITE 200, LA JOLLA CA 92037
Kathryn J Collier	director	C/O REGULUS THERAPEUTICS INC., 10614 SCIENCE CENTER DRIVE, SAN DIEGO CA 92121
Denis Drygin	officer: Chief Scientific Officer	10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Alice Shih-hou Huang	director	10628 SCIENCE CENTER DRIVE, SUITE 225, SAN DIEGO CA 92121
Growth Equity Opportunities V, Llc	10 percent owner	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Ali Behbahani	10 percent owner	5425 WISCONSIN AVE, CHEVY CHASE MD 20815
Mohamad Makhzoumi	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025
Paul Edward Walker	director	1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Florence Anthony A. Jr.	10 percent owner	5425 WISCONSIN AVENUE, SUITE 800, CHEVY CHASE MD 20815
Scott D Sandell	10 percent owner
Peter W. Sonsini	10 percent owner	2855 SAND HILL ROAD, MENLO PARK CA 94025